Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18903345 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | October 2024 | December 2024 | Allow | 2 | 1 | 0 | Yes | No |
| 18254190 | 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | May 2023 | November 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 18033954 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | April 2023 | March 2026 | Allow | 34 | 1 | 0 | No | No |
| 18135405 | METHODS FOR TREATING LUNG INFECTIONS AND INFLAMMATION | April 2023 | February 2026 | Allow | 34 | 1 | 0 | Yes | No |
| 18297081 | OPIOID RECEPTOR MODULATORS | April 2023 | September 2024 | Allow | 17 | 0 | 1 | No | No |
| 18025465 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | March 2023 | March 2026 | Allow | 36 | 1 | 0 | No | No |
| 18164813 | RAS INHIBITORS | February 2023 | October 2024 | Allow | 21 | 0 | 0 | No | No |
| 18018761 | Salts Of Nitrogen-Containing Heterocyclic Compound, And Solid Forms Of Salts, Pharmaceutical Composition And Use Thereof | January 2023 | February 2026 | Allow | 36 | 1 | 0 | Yes | No |
| 18155343 | A METHOD FOR MANUFACTURING DEUTERATED BORON COMPOUND | January 2023 | June 2025 | Abandon | 29 | 2 | 0 | No | No |
| 18068728 | METHOD FOR PURIYFING WASTE N-METHYL-2-PYRROLIDONE | December 2022 | October 2025 | Abandon | 34 | 2 | 0 | No | No |
| 18068151 | CONTINUOUS-FLOW PREPARATION METHOD OF DIOL SULFONE | December 2022 | February 2026 | Abandon | 38 | 3 | 0 | No | No |
| 18080744 | METHOD FOR SYNTHESIZING AN ANTI-CANCER COMPOUND THROUGH A ONE-POT REACTION | December 2022 | February 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18000951 | PYRIDINE-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | December 2022 | February 2026 | Abandon | 38 | 0 | 1 | No | No |
| 17927584 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | November 2022 | February 2026 | Allow | 39 | 1 | 0 | No | No |
| 17926379 | CONTINUOUS FLOW SONOGASHIRA COUPLING SYNTHESIS METHOD | November 2022 | March 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17982452 | ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (MDAI) | November 2022 | March 2025 | Abandon | 28 | 1 | 0 | No | No |
| 17996265 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | October 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17918536 | SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | October 2022 | January 2026 | Abandon | 40 | 1 | 0 | No | No |
| 18045072 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | October 2022 | February 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17958845 | SYSTEMS AND METHODS FOR REMOVING OR REDUCING WATER IN MIXTURES THAT INCLUDE T-BUTYL HYDROPEROXIDE | October 2022 | July 2025 | Allow | 34 | 3 | 0 | No | No |
| 17916645 | HA-PACLITAXEL CONJUGATE FOR TREATMENT OF MESOTHELIOMA | October 2022 | January 2026 | Allow | 40 | 1 | 0 | No | No |
| 17910864 | METHODS FOR TREATING CANCER BY INHIBITING CARM1 | September 2022 | January 2026 | Allow | 41 | 2 | 1 | No | No |
| 17909792 | GPR52 MODULATOR COMPOUNDS | September 2022 | February 2026 | Allow | 41 | 2 | 0 | No | No |
| 17800013 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | August 2022 | February 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17875776 | GPR119 AGONISTS | July 2022 | June 2024 | Allow | 22 | 1 | 0 | No | No |
| 17758577 | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy | July 2022 | September 2025 | Allow | 39 | 1 | 0 | No | No |
| 17786963 | EGFR INHIBITORS | June 2022 | August 2025 | Allow | 38 | 1 | 0 | No | No |
| 17784078 | COMPOSITIONS AND METHODS FOR SUBSTITUTED 7-(PIPERAZIN-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE ANALOGS AS INHIBITORS OF KRAS | June 2022 | October 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17783863 | COMPOUND AS CYCLIN-DEPENDENT KINASE 9 INHIBITOR AND USE THEREOF | June 2022 | November 2025 | Allow | 41 | 2 | 0 | No | No |
| 17782867 | COMBINED USE OF SODIUM TRANS-[TETRACHLORIDOBIS(1H-INDAZOLE)RUTHENATE(III)] AND ETOMOXIR FOR TREATING CANCERS | June 2022 | November 2025 | Allow | 41 | 1 | 0 | No | No |
| 17782214 | SUBSTITUTED NUCLEOSIDE ANALOGS AS PRMT5 INHIBITORS | June 2022 | March 2026 | Allow | 45 | 3 | 1 | No | No |
| 17782438 | SSTR5 ANTAGONISTS | June 2022 | December 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17782117 | ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | June 2022 | November 2025 | Allow | 42 | 1 | 1 | No | No |
| 17781629 | N-(FURAN-2-YLMETHYL)-7H-PURIN-6-AMINE FOR TREATMENT OF CIRCADIAN RHYTHM DISEASES, DISORDERS AND DYSFUNCTIONS | June 2022 | January 2026 | Allow | 43 | 2 | 1 | Yes | No |
| 17779973 | SULFONAMIDE COMPOUNDS TARGETING CD73 AND ADENOSINE RECEPTORS | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17749233 | KDM4 INHIBITORS | May 2022 | August 2025 | Allow | 39 | 2 | 1 | No | No |
| 17777716 | HETEROARYL COMPOUNDS | May 2022 | July 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17777272 | B-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | May 2022 | August 2025 | Allow | 39 | 2 | 0 | No | No |
| 17755602 | COMBINATION THERAPY FOR TREATING CANCER | May 2022 | August 2025 | Allow | 40 | 1 | 0 | No | No |
| 17773749 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | May 2022 | March 2026 | Allow | 46 | 2 | 1 | Yes | No |
| 17773215 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALT THEREOF | April 2022 | February 2026 | Allow | 46 | 2 | 1 | No | No |
| 17773325 | COMPOUND COMPRISING EZH2 INHIBITOR AND E3 LIGASE BINDER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EZH2-ASSOCIATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | April 2022 | September 2025 | Allow | 41 | 2 | 0 | No | No |
| 17773201 | LIQUID ORAL FORMULATION OF BUMETANIDE | April 2022 | January 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17772493 | CD38 INHIBITORS | April 2022 | February 2026 | Abandon | 46 | 1 | 1 | No | No |
| 17770714 | METTL3 MODULATORS | April 2022 | October 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17770928 | GABAA POSITIVE ALLOSTERIC MODULATOR COMPOUNDS, METHODS OF MAKING, AND USES THEREOF | April 2022 | December 2025 | Allow | 44 | 2 | 0 | No | No |
| 17770267 | Superebastine Against Therapy Resistant Prostate Cancer | April 2022 | October 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17769814 | N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | April 2022 | July 2025 | Allow | 39 | 1 | 0 | No | No |
| 17769293 | MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | April 2022 | December 2025 | Abandon | 44 | 0 | 1 | Yes | No |
| 17767474 | THERAPEUTIC COMBINATIONS COMPRISING DERIVATIVES OF OXAZAPHOSPHORINES FOR THE TREATMENT OF CANCER | April 2022 | November 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17767278 | SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESSES THEREOF | April 2022 | November 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17767119 | ANTIMICROBIAL AND ANTIVIRAL EFFECTS OF C2-C7 ALKYL BORONIC ACIDS | April 2022 | December 2025 | Allow | 44 | 1 | 0 | No | No |
| 17754591 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2-YL} METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | April 2022 | December 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17766147 | MCL1 INHIBITORS AND USES THEREOF | April 2022 | March 2026 | Abandon | 47 | 1 | 1 | No | No |
| 17765737 | PYRIMIDINEDIONE DERIVATIVES | March 2022 | October 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17761631 | PREPARATION FOR REMOVAL AND/OR PREVENTION OF AN INFECTION ASSOCIATED WITH STAPHYLOCOCCUS EPIDERMIDIS | March 2022 | October 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17684626 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | March 2022 | July 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17639817 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | March 2022 | January 2026 | Abandon | 46 | 0 | 1 | No | No |
| 17683718 | METHODS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS CAUSED BY SARS-COV-2 VIRUS BY ADMINISTRATION OF TAFENOQUINE | March 2022 | February 2026 | Allow | 47 | 2 | 0 | Yes | No |
| 17639481 | DOSAGE FORMS FOR TYK2 INHIBITORS | March 2022 | November 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17639154 | P-GP INDUCERS AS PROTECTORS AGAINST CHEMOTHERAPY-INDUCED SIDE EFFECTS, SUCH AS PERIPHERAL NEUROPATHY (CIPN) AND HAIR LOSS | February 2022 | June 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17639295 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SOLID CANCER COMPRISING EPIDITHIODIOXOPIPERAZINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | February 2022 | January 2026 | Abandon | 47 | 1 | 0 | No | No |
| 17637000 | Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient | February 2022 | August 2025 | Allow | 42 | 1 | 0 | No | No |
| 17636164 | 2-AMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | February 2022 | July 2025 | Allow | 41 | 1 | 0 | No | No |
| 17634717 | CRYSTALLINE FORMS OF PYRIMIDINO DIAZEPINE DERIVATIVE | February 2022 | October 2025 | Allow | 44 | 2 | 0 | No | No |
| 17633679 | TRUNCATED ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | February 2022 | August 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17632612 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | February 2022 | August 2025 | Allow | 43 | 2 | 0 | No | No |
| 17590603 | METHODS OF TREATING CANCER | February 2022 | June 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17631774 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) AND USES THEREOF | January 2022 | July 2025 | Allow | 41 | 1 | 1 | No | No |
| 17629939 | SYNTHESIS OF PRO-RESOLVING ANALOGS AND COMPOSITIONS THEREFOR | January 2022 | September 2025 | Allow | 44 | 2 | 0 | No | No |
| 17629707 | PHOTO INDUCED CONTROL OF PROTEIN DESTRUCTION | January 2022 | October 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17629075 | 1,2-BIS(DIPHENYLPHOSPHINOALKYLAMIDO)-1,2-DISUBSTITUTED ETHANE, AND ITS SYNTHESIS AND APPLICATION | January 2022 | December 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17628659 | 7,8-DIHYDRO-4H-PYRAZOLO[4,3-c]AZEPINE-6-ONE COMPOUNDS | January 2022 | June 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17627275 | METHOD FOR OBTAINING AMORPHOUS REMIMAZOLAM BESYLATE | January 2022 | March 2025 | Allow | 38 | 1 | 0 | No | No |
| 17625487 | COMPOSITION COMPRISING O-CYCLIC PHYTOSPHINGOSINE-1-PHOSPHATE FOR PREVENTING OR TREATING PARKINSON'S DISEASE | January 2022 | March 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17624052 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | December 2021 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17623573 | REMEDY FOR HAIR GROWTH ENHANCING | December 2021 | July 2025 | Allow | 42 | 1 | 0 | No | No |
| 17621877 | Fused Imidazole Derivatives as IL-17 Modulators | December 2021 | February 2026 | Allow | 50 | 3 | 1 | Yes | No |
| 17558108 | EGFR INHIBITOR FOR MEDICAL USE | December 2021 | January 2026 | Abandon | 49 | 2 | 0 | No | No |
| 17557008 | CAMPTOTHECIN-BASED DIMER COMPOUND, ANTICANCER DRUG AND METHOD OF ELIMINATING CANCER STEM CELL | December 2021 | May 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17620226 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | December 2021 | October 2025 | Allow | 46 | 1 | 1 | No | No |
| 17644187 | NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA | December 2021 | March 2025 | Allow | 39 | 1 | 0 | No | No |
| 17618042 | PRMT5 INHIBITORS | December 2021 | July 2025 | Allow | 43 | 1 | 1 | No | No |
| 17596151 | PYRROLOPYRIMIDINE COMPOUND AND USE THEREOF | December 2021 | April 2025 | Allow | 40 | 1 | 0 | No | No |
| 17596023 | NON-HYGROSCOPIC CRYSTALLINE SALTS OF A PYRAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | December 2021 | May 2025 | Allow | 42 | 1 | 0 | No | No |
| 17614240 | COMPOUND AND PRODUCTION METHOD THEREOF, AFX-TYPE ZEOLITE AND PRODUCTION METHOD THEREOF, AND HONEYCOMB STACKED CATALYST | November 2021 | April 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17613648 | BISAMINOQUINOLINES AND BISAMINOACRIDINES COMPOUNDS AND METHODS OF THEIR USE | November 2021 | March 2025 | Allow | 40 | 1 | 1 | No | No |
| 17529617 | SYNERGISTIC MIXTURES FOR FUNGAL CONTROLS IN CEREALS | November 2021 | October 2024 | Allow | 35 | 4 | 1 | Yes | No |
| 17608907 | MIXTURE OF ISOMERS OF AMINAPHTONE, ANALYTICAL METHOD FOR IDENTIFYING THEM AND PHARMACEUTICAL COMPOSITION COMPRISING SAID ISOMERS | November 2021 | August 2025 | Allow | 46 | 2 | 0 | No | No |
| 17608981 | USE OF INHIBITORS OF YAP/TAZ FOR THE TREATMENT OF CANCER | November 2021 | October 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17607940 | MODULATORS OF TREX1 | November 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17607325 | PIM KINASE INHIBITOR COMPOSITIONS AND USES THEREOF | October 2021 | April 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17513232 | IONIC CHANNEL MODULATION AS A METHOD FOR TREATING TUMORS THROUGH INFLAMMASOME ACTIVATION | October 2021 | January 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17606827 | POLYMORPHS OF 7-CYCLOPENTYL-N,N-DIMETHYL-2-{[5-(PIPERAZIN-1-YL) PYRIDIN-2-YL]-AMINO}-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR THE PREPARATION THEREOF | October 2021 | December 2024 | Allow | 38 | 1 | 0 | No | No |
| 17606658 | A GRK2 PROTEIN INHIBITOR COMPOUND AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | October 2021 | April 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17606154 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | October 2021 | March 2025 | Allow | 41 | 1 | 1 | No | No |
| 17606026 | COMBINATION THERAPEUTIC REGIMENS WITH 1,6-DIBROMO-1,6-DIDEOXY-DULCITOL | October 2021 | May 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17605812 | PROCESS FOR THE AQUEOUS EXTRACTION OF BIOSURFACTANTS FROM CORN STEEP LIQUOR | October 2021 | July 2025 | Allow | 45 | 3 | 0 | No | No |
| 17604540 | MANUFACTURING PROCESS FOR AMIFAMPRIDINE PHOSPHATE | October 2021 | March 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17603550 | CD73 INHIBITORS | October 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner RZECZYCKI, PHILLIP MATTHEW works in Art Unit 1625 and has examined 30 patent applications in our dataset. With an allowance rate of 60.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner RZECZYCKI, PHILLIP MATTHEW's allowance rate of 60.0% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by RZECZYCKI, PHILLIP MATTHEW receive 1.23 office actions before reaching final disposition. This places the examiner in the 16% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by RZECZYCKI, PHILLIP MATTHEW is 42 months. This places the examiner in the 18% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +46.2% benefit to allowance rate for applications examined by RZECZYCKI, PHILLIP MATTHEW. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 37.5% of applications are subsequently allowed. This success rate is in the 85% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 66.7% of cases where such amendments are filed. This entry rate is in the 90% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 200.0% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.